INFORMATION DISCLOSURE STATEMENT BY APPLICANT

T BY APPLICANT
OIPE
SCHOOL SCHOOL
NOV 2 8 2001
RADEMARKS

· · · · · · · · · · · · · · · · · · ·	
ATTY. DOCKET NO. 1662/52202	SERIAL NO. 309/829,621 0
APPLICANT FLASHNER-BARAK	2 9 2 TER 160
FILING DATE April 10, 2001	GROUP 29 11 11 1615 C


U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUB- CLASS	FILING DATE*
Sterl	4,345,588	August 24, 1982	' Widder et al.	. (1	
	4,492,720	January 8, 1985	Mosier			
	5,684,169	November 4, 1997	Hamada et al.			_
	5,415,869	May 16, 1995	Straubinger et al.			
	5,580,575	December 3, 1996	Unger et al.			
	5,504,102	April 2, 1996	Agharkar et al.			
	5,407,683	April 18, 1995	Shively			
	5,641,803	June 24, 1997	Carretta et al.			
	5,621,001	April 15, 1997	Canetta et al.			
	5,496,846	March 5, 1996	Wilson et al.			
	5,696,153	December 9, 1997	· Ainsworth et al.			
	5,846,565	December 8, 1998	Brem et al.			
	5,626,862	May 6, 1997	Brem et al.			
	5,651,986	July 29, 1997	Brem et al.			
	5,888,530	March 30, 1999	Netti et al.	1		
V	5,470,311	November 28, 1995	Setterstrom et al.			

^{* -} if pertinent

FOREIGN PATENT DOCUMENTS

						TRANSLATION	
EXAMINER INITIAIA	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	YES	NO
du	WO99/13914	March 25, 1999	PCT		1		
4	WO00/61141	Oct. 19, 2000	PCT				



TECH CENTER 16	NOV 2 9 2	RECEN
100/29d	001	/El

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
Heil	Seisuke Kumagai; Toru Sugiyama; Takashi Nishida, Kimio Ushijima and Michiaki Yakushiji, "Improvement of Intraperitoneal Chemotherapy for Rat Ovarian Cancer Using Cisplatin-containing Microspheres", Jpn. J. Cancer Res. 87, April 1996, pages 412-417
	Anand Babu Dhanikula, Ramesh Panchagnula, "Localized paclitaxel delivery", International Journal of Pharmaceutics 183, 1999, pages 85-100
	Au et al., Cancer Research, 1998, 58(10), pages 2141-2148
V	Sarosy and Reed, J Natl Med Assoc (1993) 85(6), pages 427-431

EXAMINER AMULA

DATE CONSIDERED / 27/0

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.